

Bu proje Avrupa Birliği ve Türkiye Cumhuriyeti tarafından finanse edilmektedir This project is co-funded by the European Union and the Republic of Türkiye



Türkiye in Horizon 2020 Phase II

ERA-NET TRANSCAN-3 Project

Silvia Paradisi (IT-MoH - ISS, Italy)

TRANSCAN-3 JTC2023 International Info Day and Networking Event, 16 May 2023







TRANSCAN Network development since 2011



The ERA-NETs (European Research Area Network) are projects funded by the European Commission to promote transnational funding on demanding reasearch areas.

The ERA-NET scheme aims at developing and strengthening the coordination of national and regional research programmes.

Joint Transnational Calls based on an international peer review evaluation process should contribute to increasing the quality of research, increasing the level of funding for challenges which no Member States can tackle alone and avoiding the duplication of research funding.

This collaborative approach enables research groups from different countries to work together on specific problems, facilitating the exchange of ideas and leveraging cross-border expertise and mobility for mutual benefit.

The ERA-NET on translational cancer research was initiated in 2011

TRANSCAN → 2011-2014 (3 Joint Transnational Calls)

(co-fund) TRANSCAN-2 \rightarrow 2015- 2021 (4 Joint Transnational Calls)

Achievements of TRANSCAN and TRANSCAN-2 funding programmes (2011-2017)





7 calls for proposals



85.2 million € invested



by 28 funders from 19 countries



406 research groups





TRANSCAN-3

ERA-NET: Sustained collaboration of national and regional programmes in cancer research

Funded by the European Union's Horizon 2020 research and innovation programme

From March 2021 to February 2026

Coordinator: Ministry of Health, Italy

- > Coordinating national and regional funding programs for translational cancer research.
- > Promoting a collaborative approach among scientific teams across borders.
- > Ensuring efficient use of available resources and avoiding duplication of efforts.
- ➤ Aim to produce impactful results of higher quality and significance.




TRANSCAN-3 - 31 Partners* from 20 Countries

15 Member States: Austria, Belgium, Estonia, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Poland, Portugal, Romania, Slovakia, Spain

3 Associated countries: Israel, Norway, Turkey

2 Third countries: Canada, Taiwan



TRANSCAN-3 - Joint Transnational Calls



JTC 2021 (EU co-funded) on: Next generation cancer immunotherapy: targeting the tumour microenvironment

- > Funded projects: 20 Research groups: 107
- Funding organisations: **23** from 15 Countries
- ➤ Total budget from funding organisations: **25.9** million €
- ➤ Budget from the European Commission: **3.7** million €

Discover more. Check out our newsletter n. 3

JTC 2022 on: Novel translational approaches to tackle the challenges of hard-to-treat cancers from early diagnosis to therapy

- Funded projects: 14 Research groups: 64
- Funding organisations: **22** from 15 Countries
- ➤ Total budget from funding organisations: **14.9** million €

JTC 2023 on: Translational research on cancer epigenetics

Participation in JTC 2021 and JTC 2022 calls



JTC 2021

Total submitted eligible pre-proposals: 161

Projects invited to the full proposal stage: 56

Total funded projects: 20

Success rate first phase: 12%
Success rate second phase: 35%

JTC 2022

Total submitted eligible pre-proposals: 70

Projects invited to the full proposal stage: 40

Total funded projects: 14

Success rate first phase: 20%
Success rate second phase: 35%



Thank you!

Keep in touch with us!

Head to our website, subscribe to our newsletter, and follow us on social media to stay in the know.

https://transcan.eu

https://docs.google.com/forms/d/e/1FAIpQLSdTNxohqdb LFoyvl MIig0IxBZDV58J VeO- wH3ndLM1AYQ/viewform

https://twitter.com/transcanproject

https://www.linkedin.com/company/transcan-3/

